Versione italiana
medico 
Prof. Claus Garbe
|
Prof. Claus Garbe
Head of the Division of Dermatooncology
Eberhard Karls University, Tuebingen (Germany)
specialty: Dermatology, Dermatological Oncology
|
[en]
|
Metastatic Melanoma: 5-year survival rates may soon reach 60% Prof. Claus Garbe congresso: At the beginning of this decade, the average survival of patients with metastatic melanoma was 7 months and the 5-year rate was 3%. Thanks to the introduction of new drugs such as Vemurafenib and Ipilimumab, the survival rate rose to 20% and now, with PD-1 and CTLA-4 antibodies and combined targeted treatments based on BRAF and MEK inhibitors, survival is 40-50% . Prof. Garbe explains why a 5-year rate of 60-70% could be achieved in the near future. |
